Hernán Carol

4.5k citations

93 papers · 3.0k · h-index 35

Impact in

Neurology top 2%
- Neuroblastoma Research and Treatments
Oncology top 5%
- CAR-T cell therapy research
- Cancer-related Molecular Pathways

Papers in

Molecular Biology 34
- Cancer therapeutics and mechanisms 8
- Cell death mechanisms and regulation 7
- PI3K/AKT/mTOR signaling in cancer 6
Oncology 19

Co-authors: Richard B. Lock (81 shared papers)Malcolm A. Smith (75 shared papers)Peter J. Houghton (72 shared papers)C. Patrick Reynolds (59 shared papers)John M. Maris (62 shared papers)Stephen T. Keir (59 shared papers)E. Anders Kolb (56 shared papers)Richard Görlick (59 shared papers)
Journals: Pediatric Blood & Cancer (47 papers)Molecular Cancer Therapeutics (8 papers)Cancer Research (6 papers)Clinical Cancer Research (5 papers)Blood (5 papers)
Partner nations: United States Australia Uruguay

In The Last Decade

Hernán Carol

91 papers receiving 3.0k citations

Peers

Countries citing papers authored by Hernán Carol

Since Specialization

Citations

This map shows the geographic impact of Hernán Carol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hernán Carol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hernán Carol more than expected).

Fields of papers citing papers by Hernán Carol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hernán Carol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hernán Carol. The network helps show where Hernán Carol may publish in the future.

Co-authors

The 25 scholars most cited alongside Hernán Carol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hernán Carol Line = papers co-authored together Hernán Carol links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 93 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) Pediatric Blood & Cancer ·John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Richard B. Lock, Hernán Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, Jianrong Wu, Malcolm A. Smith, Peter J. Houghton	2010	179
2	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith	2008	138
3	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith	2007	126
4	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia Blood ·Seong Lin Khaw, Santi Suryani, Kathryn Evans, Jennifer Richmond, Alissa K. Robbins, Raushan T. Kurmasheva, Catherine A. Billups, Stephen W. Erickson, Yuelong Guo, Peter J. Houghton, Malcolm A. Smith, Hernán Carol, Andrew W. Roberts, David C.S. Huang, Richard B. Lock	2016	116
5	Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program Pediatric Blood & Cancer ·Richard B. Lock, Hernán Carol, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	99
6	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Nino Keshelava, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	2007	98
7	Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 PLoS ONE ·Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernán Carol, Ingrid Boehm, Hongbo Lu, Sergej Konoplev, Wendy Fang, Patrick A. Zweidler‐McKay, Dario Campana, Gautam Borthakur, Carlos E. Bueso‐Ramos, Elizabeth J. Shpall, Deborah A. Thomas, Craig T. Jordan, Hagop M. Kantarjian, William R. Wilson, Richard B. Lock, Michael Andreeff, Marina Konopleva	2011	98
8	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program Clinical Cancer Research ·Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton	2014	90
9	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) Clinical Cancer Research ·Yaël P. Mossé, Elizabeth Fox, (unknown), Joel M. Reid, Stephanie L. Safgren, Hernán Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel	2019	83
10	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program Molecular Cancer Therapeutics ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith	2010	79
11	Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernán Carol, Richard B. Lock, Doris A. Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine A. Billups, Malcolm A. Smith	2010	78
12	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer Cancer Chemotherapy and Pharmacology ·Hernán Carol, Ingrid Boehm, C. Patrick Reynolds, Min H. Kang, John M. Maris, Christopher L. Morton, Richard Görlick, E. Anders Kolb, Stephen T. Keir, Jianrong Wu, A. E. Wozniak, Yu Yang, Mark Manfredi, Jeffrey Ecsedy, Jianmin Wang, Geoffrey Neale, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	2011	77
13	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program Pediatric Blood & Cancer ·Peter J. Houghton, Min H. Kang, C. Patrick Reynolds, Christopher L. Morton, E. Anders Kolb, Richard Görlick, Stephen T. Keir, Hernán Carol, Richard B. Lock, John M. Maris, Catherine A. Billups, Malcolm A. Smith	2011	71
14	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, Min H. Kang, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Christopher DesJardins, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith	2013	63
15	Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program Pediatric Blood & Cancer ·E. Anders Kolb, Richard Görlick, Richard B. Lock, Hernán Carol, Christopher L. Morton, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Catherine A. Billups, Malcolm A. Smith, Peter J. Houghton	2010	60
16	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673 Pediatric Blood & Cancer ·Malcolm A. Smith, Oliver Hampton, C. Patrick Reynolds, Min H. Kang, John M. Maris, Richard Görlick, E. Anders Kolb, Richard B. Lock, Hernán Carol, Stephen T. Keir, Jianrong Wu, Raushan T. Kurmasheva, David A. Wheeler, Peter J. Houghton	2014	58
17	The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia Clinical Cancer Research ·Hernán Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	2013	57
18	Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine Vaccine ·José A. Chabalgoity, Marı́a Moreno, Hernán Carol, Gordon Dougan, Carlos E. Hormaeche	2000	55
19	Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program Pediatric Blood & Cancer ·Nino Keshelava, Peter J. Houghton, Christopher L. Morton, Richard B. Lock, Hernán Carol, Stephen T. Keir, John M. Maris, C. Patrick Reynolds, Richard Görlick, E. Anders Kolb, Jianrong Wu, Malcolm A. Smith	2009	50
20	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program Pediatric Blood & Cancer ·Hernán Carol, C. Patrick Reynolds, Min H. Kang, Stephen T. Keir, John M. Maris, Richard Görlick, E. Anders Kolb, Catherine A. Billups, Brian Geier, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	2012	50

About Hernán Carol

Hernán Carol is a scholar working on Molecular Biology, Oncology, Public Health, Environmental and Occupational Health, Neurology and Parasitology, having authored 93 papers that have together received 3.0k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (18 papers), Neuroblastoma Research and Treatments (12 papers), Cancer therapeutics and mechanisms (8 papers), Parasitic infections in humans and animals (7 papers), Cell death mechanisms and regulation (7 papers), Toxoplasma gondii Research Studies (7 papers), Parasitic Infections and Diagnostics (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Neurology (498 citations), Oncology (786 citations), Hematology (332 citations), Cancer Research (347 citations) and Molecular Biology (1.5k citations). Hernán Carol has collaborated with scholars based in United States, Australia and Uruguay. Frequent co-authors include Richard B. Lock, Malcolm A. Smith, Peter J. Houghton, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, E. Anders Kolb, Richard Görlick, Christopher L. Morton and Min H. Kang. Their work appears in journals such as Pediatric Blood & Cancer, Molecular Cancer Therapeutics, Cancer Research, Clinical Cancer Research and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Hernán Carol

Impact in

Papers in i

In The Last Decade

Hernán Carol

Peers

Countries citing papers authored by Hernán Carol

Fields of papers citing papers by Hernán Carol

All Works

About Hernán Carol

Explore authors with similar magnitude of impact

Papers in